6/30/2015 - 11:33 AM EST - RepliCel Life Sciences Inc. : announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections. RCT-01 is comprised of non-bulbar dermal sheath cells isolated from hair follicles via a small biopsy taken from the back of the participant's head. RepliCel Life Sciences Inc.
shares V.RP are trading down $0.02 at $0.39.
